These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38468481)

  • 1. Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates.
    Elsisi GH; Waleed AA; Shehhy WA; Farghaly M
    J Med Econ; 2024; 27(sup1):23-34. PubMed ID: 38468481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.
    Neupane B; Shukla P; Slim M; Martin A; Petri M; Bertsias GK; Kim AHJ; Fanouriakis A; Levy RA; Chauhan D; Ballew N
    Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37147022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.
    Pierotti F; Palla I; Treur M; Pippo L; Turchetti G
    PLoS One; 2015; 10(10):e0140843. PubMed ID: 26488751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of systemic lupus erythematosus in United Arab Emirates.
    Alansari A; Hannawi S; Aldhaheri A; Zamani N; Elsisi GH; Aldalal S; Naeem WA; Farghaly M
    J Med Econ; 2024; 27(sup1):35-45. PubMed ID: 38468482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain].
    Díaz-Cerezo S; García-Aparicio ÁM; Parrondo J; Vallejo-Aparicio LA
    Farm Hosp; 2015 May; 39(3):161-70. PubMed ID: 26005892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.
    Bruce IN; Golam S; Steenkamp J; Wang P; Worthington E; Desta B; Psachoulia K; Erhardt W; Tummala R
    J Comp Eff Res; 2022 Jul; 11(10):765-777. PubMed ID: 35546484
    [No Abstract]   [Full Text] [Related]  

  • 7. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
    Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.
    Specchia ML; de Waure C; Gualano MR; Doria A; Turchetti G; Pippo L; Di Nardo F; Capizzi S; Cadeddu C; Kheiraoui F; Iaccarino L; Pierotti F; Palla I; Veneziano MA; Gliubizzi D; Sferrazza A; Nicolotti N; Porcasi R; La Torre G; Di Pietro ML; Ricciardi W
    Biomed Res Int; 2014; 2014():704207. PubMed ID: 25243173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
    Lokhandwala T; Yue B; Coutinho AD; Bell CF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study.
    Alsuwayegh A; Almaghlouth IA; Almasaoud MA; Alzaid AS; Alsuhaibani AA; Almana LH; Alabdulkareem SM; Abudahesh JA; AlRuthia Y
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.